Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks

Molecular Nutrition and Food Research

Volumn 57, Issue 1, 2013, Pages 100-113

  Rietjens, Ivonne M C M ^a   Sotoca, Ana M ^b   Vervoort, Jacques ^a   Louisse, Jochem ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Isoflavones; Mode of action

Indexed keywords

COREPRESSOR PROTEIN; DAIDZEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; HISTONE; ISOFLAVONE DERIVATIVE; MICRORNA; PHYTOESTROGEN; PLANT EXTRACT;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; DNA METHYLATION; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW; RISK FACTOR; SOYBEAN;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CO-REPRESSOR PROTEINS; DNA METHYLATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; HISTONES; HUMANS; ISOFLAVONES; MICRORNAS; NEOPLASMS; PHYTOESTROGENS; PLANT EXTRACTS; RISK FACTORS; SOYBEANS;

EID: 84872278176     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200439     Document Type: Review

References (161)

1. Lock, M., Contested meanings of the menopause. Lancet 1991, 337, 1270-1272.
2. Imamov, O., Shim, G.-J. M., Warner, M., Gustafsson, J.-Å., Estrogen receptor beta in health and disease. Biol. Reproduc. 2005, 73, 866-871.
3. Osborne, C. K., Zhao, H. H., Fuqua, S. A. W., Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol. 2000, 18, 3172-3186.
4. Effenberger, K. E., Johnsen, S. A., Monroe, D. G., Spelsberg, T. C. et al., Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. J. Steroid Biochem. Mol. Biol. 2005, 96, 387-399.
5. Writing Group for Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288, 321-333.
6. Shumaker, S. A., Reboussin, B. A., Espeland, M. A., Rapp, S. R. et al., The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Controlled Clinical Trials 1998, 19, 604-621.
7. Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L. et al., WHIMS investigators, estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289, 2651-2662.
8. Million Women Study Collaborators, Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362, 419-427.
9. Turner, J. V., Agatonovic-Kustrin, S., Glass, B. D., Mole-cular aspects of phytoestrogen selective binding at estrogen receptors. J. Pharmaceut. Sci. 2007, 96, 1879-1885.
10. Goldstein, M. S., Glik, D., Use of and satisfaction with ho-meopathy in a patient population. Altern. Ther. Health Med. 1998, 4, 60-65.
11. Kass-Annese, B., Alternative therapies for menopause. Clin. Obstet. Gynecol. 2000, 43, 162-183.
12. Galluzo, P., Marino, M., Nutritional flavonoids impact on nuclear and extracellular estrogen receptor activities. Genes Nutr. 2006, 1, 161-176.
13. Kuiper, G. G. J. M., Lemmen, J. G., Carlsson, B., Corton, J. C. et al., Interaction of estrogenic chemicals and phyto-estrogens with estrogen receptor β. Endocrinology, 1998, 139, 4252-4263.
14. Eisenbrand, G., Isoflavones as phytoestrogens in food supplements and dietary foods for special medical purposes. Mol. Nutr. Food Res. 2007, 52, 1305-1312.
15. Krebs, E. E., Ensrud, K. E., MacDonald, R., Wilt, T. J., Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet. Gynecol. 2004, 104, 824-36.
16. Hargreaves, D. F., Potten, C. S., Harding, C., Shaw, L. E. et al., Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J. Clin. Endocrinol. Metab. 1999, 84, 4017-4024.
17. Petrakis, N. L., Barnes, S., King, E. B., Lowenstein, J. et al., Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 785-794.
18. Persson, I., Estrogens in the causation of breast, endometrial and ovarian cancers-evidence and hypotheses from epidemiological findings. J. Steroid. Biochem. Mol. Biol. 2000, 74, 357-364.
19. Bonkhoff, H., Fixemer, T., Hunsicker, I., Remberger, K., Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol. 1999, 155, 641-647.
20. Maffini, M. V., Rubin, B. S., Sonnenschein, C., Soto, A. M., Endocrine disruptors and reproductive health: the case of bisphenol-A. Mol. Cell. Endocrinol. 2006, 254-255, 179-186.
21. Hsieh, C. Y., Santell, R. C., Haslam, S. Z., Helferich, W. G., Estrogenic effects of genistein on the growth of estrogen receptor positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998, 58, 3833-3838.
22. Allred, C. D., Allred, K. F., Ju, Y. H., Virant, S. M. et al., Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001, 61, 5045-5050.
23. Allred, C. D., Ju, Y. H., Allred, K. F., Chang, J. et al., Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis 2001, 22, 1667-1673.
24. Ju, Y. H., Allred, C. D., Allred, K. F., Karko, K. L. et al., Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J. Nutr. 2001, 131, 2957-2962.
25. Ju, Y. H., Doerge, D. R., Allred, K. F., Allred, C. D. et al., Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002, 62, 2474-2477.
26. Ju, Y. H., Allred, K. E., Allred C. D., Helferich W. G., Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 2006, 27, 1292-1299.
27. Allred, C. D., Allred, K. F., Ju, Y. H., Clausen, L. M. et al., Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis 2004, 25, 211-218.
28. Zava, D. T., Duwe, G., Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr. Cancer 1997, 27, 31-40.
29. Sotoca, A. M., Ratman, D., Van der Saag, P., Ström, A. et al., Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ERbeta ratio. J. Steroid Biochem. Mol. Biol. 2008, 112, 171-178.
30. Adams, S. M., Aksenova, M. V., Aksenov, M. Y., Mactutus, C. F. et al., Soy isoflavones genistein and daidzein exert anti-apoptotic actions via a selective ER-mediated mechanism in neurons following HIV-1 Tat1-86 exposure. PLoS One 2012, 7, e37540, 1-9.
31. Cheng, G., Wilczek, B., Warner, M., Gustafsson, J.-Å. et al., Isoflavone treatment for acute menopausal symptoms. Menopause 2007, 14, 468-473.
32. Sartippour, M. R., Rao, J. Y., Apple, S., Wu, D. et al., A pilot clinical study of short-term isoflavone supplements in breast cancer patients. Nutr. Cancer 2004, 49, 59-65.
33. Messina, M., Conclusion that isoflavones exert estrogenic effects on breast tissue and may raise breast cancer risk unfounded. Mol. Nutr. Food Res. 2008, 52, 299-300.
34. Maskarinec, G., Verheus, M., Steinberg, F. M., Amato, P. et al., Various doses of soy isoflavones do not modify mammographic density in postmenopausal women. J. Nutr. 2009, 139, 981-986.
35. Helferich, W. G., Andrade, J. E., Hoagland, M. S., Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008, 16, 219-226.
36. Hilakivi-Clarke, L., Andrade, J. E., Helferich, W., Is soy consumption good or bad for the breast? J. Nutr. 2010, 140, 2326S-2334S.
37. Khan, S. A., Chatterton, R. T., Michel, N., Bryk, M. et al., Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev. Res. (Phila). 2012, 5, 309-319.
38. National Toxicology Program (NTP), NTP technical report on the toxicology and carcinogenesis study of genistein (Cas No. 466-72-0) in Sprague-Dawley rats (feed study). NTP TR 545 NIH publication No. 06-4430. Available at http://ntp.niehs.nih.gov/ntp/about_ntp/BSC/TRRS/2006/June/Board_Drafts/5 45_Web1.pdf.
39. Messina, M. J., Persky, V., Setchell, K. D. R., Barnes, S., Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr. Cancer 1994, 21, 113-131.
40. Adlercreutz, H., Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect. 1995, 103, 103-112.
41. Adlercreutz, H., Goldin, B. R., Gorbach, S. L., Hockerstedt, K. A. V. et al., Soybean phytoestrogen intake and cancer risk. J. Nutr. 1995, 125, 757S-770S.
42. Rose, D. P., Dietary fiber, phytoestrogens, and breast cancer. Nutrition 1992, 8, 47-54.
43. Xiao, C. W., Health effects of soy protein and isoflavones in humans. J. Nutr. 2008, 138, 1244S-1249S.
44. Martin, D., Song, J., Mark, C., Eyster, K., Understanding the cardiovascular actions of soy isoflavones: potential novel targets for antihypertensive drug development. Cardiovasc. Hematol. Disord. Drug Targets 2008, 8, 297-312.
45. Taku, K., Umegaki, K., Ishimi, Y., Watanabe, S., Effects of extracted soy isoflavones alone on blood total and LDL cholestrol: meta-analysis of randomized controlled trials. Therap. Clin. Risk Management 2008, 4, 1097-1103.
46. Liu, J., Ho, S. C., Su, Y., Chen, W. et al., Chen Y., effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. Bone 2009, 44, 948-953.
47. European Food Safety Authority (EFSA), Scientific opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.
48. Casidy, A., Albertazzi, P., Nielsen, I. L., Hall, W. et al., Critical review of health effects of soyabean phyto-estrogens in post-menopausal women. Proc. Nutr. Soc. 2006, 65, 76-92.
49. Shimazu, T., Inoue, M., Sasazuki, S., Iwasaki, M. et al., Plasma isoflavones and the risk of lung cancer in women: a nested case-control study in Japan. Cancer Epidem. Biomarkers & Prevention, 2011, 20, 419-427.
50. Ko, K. P., Park, S. K., Park, B., Yang, J. J. et al., Isoflavones from phytoestrogens and gastric cancer: a nested case-control study within the Korean multicenter cancer cohort. Cancer Epidem. Biomarkers & Prevention, 2010, 19, 1292-1300.
51. Severson, R. K., Nomura, A. M. Y., Grove, J. S., Stemmermann, G. N., A prospective study of demographics, diet and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989, 49, 1857-1860.
52. Lee, H. P., Gourley, L., Duffy, S. W., Esteve, J. et al., Dietary effects on breast-cancer risk in Singapore. Lancet 1995, 337, 1197-1200.
53. Kurahashi, N., Iwasaki, M., Sasazuki, S., Otani, T. et al., Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidem. Biomarkers & Prevention, 2007, 16, 538-545.
54. Yan, L., Spitznagel, E. L., Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am. J. Clin. Nutr. 2009, 89, 1155-1163.
55. Trock, B.J., Hilakivi-Clarke, L., Clarke, R., Meta-analysis of soy intake and breast cancer risk. J. Natl. Canc. Inst. 2006, 98, 459-471.
56. Wu, A. H., Yu, M. C., Pike, M. C., Epidemiology of soy exposures and breast cancer risk. Br. J. Cancer 2008, 98, 9-14.
57. Taylor, C. K., Levy, R.M., Elliott, J. C., Burnett B. P., The effect of genistein aglycon on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr. Rev. 2009, 67, 398-415.
58. Warri, A., Saarinen, N. M., Makela, S., Hilakivi-Clarke, L., Minireview. The role of early life genistein exposures in modifying breast cancer risk. Br. J. Cancer 2008, 98, 1485-1493.
59. Molzberger, A. F., Vollmer, G., Hertrampf, T., Möller, F. J. et al., In utero and postnatal exposure to isoflavones results in reduced responsivity of the mammary gland towards estradiol. Mol. Nutr. Food Res. 2012, 56, 399-409.
60. McCauley, L., Demmig-Adams, B., Breast cancer, Asian diet, and soy genistein-a matter of all or nothing? Nutr. Food Sci. 2005, 35, 28-34.
61. Magee, P.J., Is equol production beneficial to health? Proc. Nutr. Soc. 2011, 70, 10-18.
62. Ingram, D., Sanders, K., Kolybaba, M., Lopez, D., Case-control study of phyto-oestrogens and breast cancer. Lancet 1997, 350, 990-994.
63. Goodman, M. T., Shvetsov, Y. B., Wilkens, L. R., Franke, A. A. et al., Urinary phytoestrogen excretion and postmenopausal breast cancer risk: The Multiethnic Cohort Study. Cancer Prev. Res. 2009, 2, 887-894.
64. Akaza, H., Miyanaga, N., Takashima, N., Naito, S. et al., Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn. J. Clin. Oncol. 2004, 34, 86-89.
65. Ozasa, K., Nakao, M., Watanabe, Y., Hayashi, K. et al., For the JACC Study Group, serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci. 2004, 95, 65-71.
66. Wu, J., Oka, J., Ezaki, J., Ohtomo, T. et al., Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause 2007, 14, 866-874.
67. Tousen, Y., Ezaki, J., Fujii, Y., Ueno, T. et al., Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause 2011, 18, 563-574.
68. Frankenfeld, C. L., McTiernan, A., Aiello, E. J., Thomas, W. K. et al., Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1156-1162.
69. Aso, T., Equol improves menopausal symptoms in Japanese women. J. Nutr. 2010, 140, 1386S-1389S.
70. Barnes, S., Grubbs, C., Setchell, K. D. R., Carlson, J., Soybeans inhibit mammary tumors in models of breast cancer. Prog. Clin. Biol. Res. 1990, 347, 239-253.
71. Troll, W., Wiesner, R., Shellabarger, J., Holtzman, S. et al., Soybean diet lowers breast tumour incidence in irradiated rats. Carcinogenesis 1980, 1, 469-472.
72. Hawrylewicz, E. J., Huang, H. H., Blair, W. H., Dietary soybean isolate and methionine supplementation affect mammary tumor progression in rats. J. Nutr. 1991, 121(10), 1693-1698.
73. Lamartiniere, C. A., Moore, J., Holland, M., Barnes, S., Neonatal genistein chemoprevents mammary cancer. Soc. Exp. Biol. Med. 1995, 208, 120-123.
74. Hirano, T., Oka, K., Akiba, M., Antiproliferative effects of synthetic and naturally occurring flavonoids on tumour cells of the human breast carcinoma cell line, ZR-75-1. Res. Commun. Chem. Pathol. Pharmacol. 1989, 64, 69-77.
75. Paggliaci, M. C., Smacchia, M., Migliorati, G., Grignani, F. et al., Growth inhibitory effects of the natural phytoestrogen in MCF-7 human breast cancer cells. Eur. J. Cancer 1994 30A, 1675-1682.
76. Conklin, C. M. J., Bechberger, J. F., MacFabe, D., Guthrie, N. et al., Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells. Carcinogenesis 2007, 28, 93-100.
77. Peterson, G., Barnes, S., Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem. Biophys. Res. Commun. 1991, 179, 661-667.
78. Barnes, S., Peterson, G., Coward, L., Rationale for the use of genistein containing soy matrices in chemoprevention trials for breast and prostate cancer. J. Cell. Biochem. 1995, 22, 181-187.
79. Kuiper, G. G. J. M., Enmark, E., Pelto-Huikko, M., Nilsson, S. et al., Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 1996, 93, 5925-5930.
80. Ogawa, S., Inoue, S., Watanabe, T., Orimo, A. et al., Molecular cloning and characterization of human estrogen receptor beta: a potential inhibitor of estrogen action in human. Nucl. Acids Res. 1998, 26, 3505-3512.
81. Thomas, C., Gustafsson, J.-Å., The different roles of ER subtypes in cancer biology and therapy. Nat. Rev. Cancer 2011, 11, 597-608.
82. Nilsson, S., Makela, S., Treuter, E., Tujague, M. et al., Mechanisms of estrogen action. Physiol. Rev. 2001, 81, 1535-1565.
83. Williams, C., Edvardsson, K., Lewandowski, S. A., Ström, A. et al., A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 2007, 1, 1019-1032.
84. Harris, H. A., Estrogen receptor-β: recent lessons from in vivo studies. Mol. Endocrinol. 2007, 21, 1-13.
85. Pearce, S. T., Jordan, V. C., The biological role of estrogen receptors alpha and beta in cancer. Crit. Rev. Oncol./Hematol. 2004, 50, 3-22.
86. Bardin, A., Boulle, N., Lazennec, G., Vignon, F. et al., Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 2004, 11, 537-551.
87. Ström, A., Hartman, J., Foster, J. S., Kietz, S. et al., Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA 2004, 101, 1566-1571.
88. Stossi, F., Barnett, D. H., Frasor, J., Komm, B. et al., Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 2004, 145, 3473-3486.
89. Sotoca, A. M., Van den Berg, J. H. J., Vervoort, J., Van der Saag, P. et al., Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol. Sci. 2008, 105, 303-311.
90. Enmark, E., Pelto-Huikko, M., Grandien, K., Lagercrantz, S. et al., Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrin. Metab. 1997, 82, 4258-4265.
91. Leitman, D. C., Paruthiyil, S., Yuan, C., Herber, C. B. et al., Tissue-specific regulation of genes by estrogen receptors. Semin. Reprod. Med. 2012, 30, 14-22.
92. Heldring, N., Pike, A., Andersson, S., Matthews, J. et al., Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007, 87, 905-931.
93. Wood, C. E., Register, T. C., Franke, A. A., Anthony, M. S. et al., Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res. 2006, 66, 1241-1249.
94. Chen, X., Garner, S. C., Quarles, L. D., Anderson, J. J., Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J. Nutr. Biochem. 2003, 14, 342-349.
95. Anderson, J. J., Ambrose, W. W., Garner, S. C., Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc. Soc. Exp. Biol. Med. 1998, 217, 345-350.
96. Chang, E. C., Charn, T. H., Park, S. H., Helferich, W. G. et al., Estrogen receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol. Endocrinol. 2008, 22, 1032-1043.
97. Van den Berghe, W., Haegeman, G., Beneficial effects of soy isoflavones. Focus on epigenetics and anti-inflammatory effects. Soy 2008, 19, 57-60.
98. Shang, Y., Brown, M., Molecular determinants for the tissue specificity of SERMs. Science 2002, 295, 2465-2468.
99. Wilson, V. S., Bobseine, K., Gray, L. E. Jr., Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol. Sci. 2004, 81, 69-77.
100. Escande, A., Pillon, A., Servant, N., Cravedi, J.-P. et al., Eva-luation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem. Pharmacol. 2006, 71, 1459-1469.
101. Bovee, T. F. H., Helsdingen, R. J. R., Rietjens, I. M. C. M., Keijer, J. et al., Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J. Steroid Biochem. Mol. Biol. 2004, 91, 99-109.
102. Chrzan, B. G., Bradford, P. G., Phytoestrogens activate estrogen receptor beta1 and estrogenic responses in human breast and bone cancer cell lines. Mol. Nutr. Food Res. 2007, 51, 171-177.
103. Rau, K. M., Kang, H. Y., Cha, T. L., Miller, S. A. et al., The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr. Relat. Cancer 2005, 12, 511-532.
104. Monroe, D. G., Secreto, F. J., Subramaniam, M., Getz, B. J. et al., Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol. Endocrinol. 2005, 19, 1555-1568.
105. Lazennec, G., Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett. 2006, 231, 151-157.
106. Weitzmann, M. N., Pacifici, R., Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 2006, 116, 1186-1194.
107. Hartman, J., Lindberg, K., Morani, A., Inzunza, J. et al., Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006, 66, 11207-11213.
108. Imamov, O., Morani, A., Shim, G. J., Omoto, Y. et al., Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci. USA 2004, 101, 9375-9380.
109. Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R. et al., Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004, 64, 423-428.
110. Sotoca, A. M., Sollewijn-Gelpke, M. D., Boeren, S., Ström, A. et al., Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol. Cell Proteomics 2011, 10, M110.002170.
111. Kumi-Diaka, J., Rodriguez, R., Goudaze, G, Influence of genistein (4', 5, 7-trihydroxyisoflavone) on the growth and proliferation of testicular cell lines. Biol. Cell 1998, 90, 349-354.
112. Morris, S. M., Chen, J. J., Domon, O. E., McGarrity, L. J. et al., P53, mutations, and apoptosis in genistein-exposed human lymphoblastoid cells. Mut. Res./Fundamental and Mol. Mech. Mutagen. 1998, 405, 41-56.
113. Leygue, E., Dotzlaw, H., Watson, P. H., Murphy, L. C., Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 1998, 58, 3197-3201.
114. Rutherford, T., Brown, W. D., Sapi, E., Aschkenazi, S. et al., Absence of estrogen receptor-[beta] expression in metastatic ovarian cancer. Obstet. Gynecol. 2000, 96, 417-421.
115. Roger, P., Sahla, M. E., Mäkelä, S., Gustafsson, J.-Å. et al., Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001, 61, 2537-2541.
116. Lazennec, G., Bresson, D., Lucas, A., Chauveau, C. et al., ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology, 2001, 142, 4120-4130.
117. Fixemer, T., Remberger, K., Bonkhoff, H., Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. The Prostate 2003, 54, 79-87.
118. Förster, C., Makela, S., Warri, A., Kietz, S. et al., Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA 2002, 99, 15578-15583.
119. Powell, E., Shanle, E., Brinkman, A., Li, J. et al., Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ. PLos One 2012, 7, e30993, 1-13.
120. Lin, C.-Y., Ström, A., Kong, S. L., Kietz, S. et al., Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res. 2007, 9, R25.
121. Chang, E. C., Charn, T. H., Park, S.-H., Helferich, W. G. et al., Estrogen receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol. Endocrinol. 2008, 22, 1032-1043.
122. Dip, R., Lenz, S., Antignac, J.-P., Le Bizec, B. et al., Global gene expression profiles induced by phytoestrogens in human breast cancer cells. Endocr. Relat. Cancer 2008, 15, 161-173.
123. Lavigne, J., Takahashi, Y., Chandramouli, G., Liu, H. et al., Concentration-dependent effects of genistein on global gene expression in MCF-7 breast cancer cells: an oligo microarray study. Breast Cancer Res. Treatm. 2008, 110, 85-98.
124. Satih, S., Chalabi, N., Rabiau, N., Bosviel, R. et al., Gene expression profiling of breast cancer cell lines in response to soy isoflavones using a pangenomic microarray approach. Omics: J. Integrative Biol. 2010, 14, 231-232.
125. Kim, S. H., Kim, S. H., Lee, S. C., Song, Y. S., Involvement of both extrinsic and intrinsic apoptotic pathways in apoptosis induced by genistein in human cervical cancer cells. Ann. N. Y. Acad. Sci. 2009, 1171, 196-201.
126. Dolinoy, D. C., Weidman, J. R., Waterland, R. A., Jirtle, R. A., Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environm. Health Persp. 2006, 114, 567-572.
127. Attwood, J. T., Yung, R. L., Richardson, B. C., DNA methylation and the regulation of gene transcription. Cell Mol. Life Sci. 2002, 59, 241-257.
128. Fang, M. Z., Chen, D., Sun, Y., Jin, Z. et al., Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 2005, 11, 7033-7041.
129. Li, Y., Liu, L., Andrews, L. G., Tollefsbol, T. O., Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int. J. Cancer 2009, 125, 286-296.
130. King-Batoon, A., Leszczynska, J. M., Klein, C. B., Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen. 2008, 49, 36-45.
131. Majid, S., Dar, A. A., Ahmad, A. E., Hirata, H. et al., BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 2009, 30, 662-670.
132. Majid, S., Dar, A. A., Shahryari, V., Hirata, H. et al., Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-cell translocation gene 3 in prostate cancer. Cancer 2010, 116, 66-76.
133. Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V. et al., For the International Vidaza High-Risk MDS Survival Study Group, efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009, 10, 223-232.
134. Day, J. K., Bauer, A. M., desBordes, C., Zhuang, Y. et al., Genistein alters methylation patterns in mice. J. Nutr. 2002, 132, 2419S-2423S.
135. Dolinoy, D. C., Huang, D., Jirtle, R. A., Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc. Natl. Acad. Sci. USA 2007, 104, 13056-13061.
136. Duhl, D. M. J., Vrieling, H., Miller, K. A., Wolff, G. L. et al., Neomorphic agouti mutations in obese yellow mice. Nat. Genet. 1994, 8, 59-65.
137. Dolinoy, D. C., The agouti mouse model: an epigenetic biosensor for nutritional and environmental alterations on the fetal epigenome. Nutr. Rev. 2008, 66, S7-S11.
138. Qin, W., Zhu, W., Shi, H., Hewett, J. E. et al., Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women. Nutr. Cancer 2009, 61, 238-244.
139. Vanhees, K., Coort, S., Ruijters, E. J., Godschalk, R. W. et al., Epigenetics: prenatal exposure to genistein leaves a permanent signature on the hematopoietic lineage. FASEB J. 2011, 25, 797-807.
140. Felsenfeld, G., Groudine, M., Controlling the double helix. Nature 2003, 421, 448-453.
141. Hong, T., Nakagawa, T., Pan, W., Kim, M. Y. et al., Isoflavones stimulate estrogen receptor-mediated core histone acetylation. Biochem. Biophys. Res. Commun. 2004, 317, 259-264.
142. Majid, S., Kikuno, N., Nelles, J., Noonan, E. et al., Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res. 2008, 68, 2736-2744.
143. Kikuno, N., Shiina, H., Urakami, S., Kawamoto, K. et al., Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int. J. Cancer 2008, 123, 552-560.
144. Link, A., Balguer, F., Goel, A., Cancer chemoprevention by dietary polyphenols; promising role for epigenetics. Biochem. Pharmacol. 2010, 80, 1771-1792.
145. Weiss, T., Hergeth, S., Zeissler, U., Izzo, A. et al., Histone H1 variant-specific lysine methylation by G9a/KMT1C and Glp1/KMT1D. Epigen. Chromatin 2010, 24, 7-19.
146. Klinge, C. M., Jernigan, S. C., Mattingly, K. A., Risinger, K. E. et al., Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors. J. Mol. Endocrinol. 2004, 33, 387-410.
147. Huang, S., Litt, M., Felsenfeld, G., Methylation of histone H4 by arginine methyltransferase PRMT1 is essential in vivo for many subsequent histone modifications. Genes Developm. 2005, 19, 1885-1893.
148. Martin, C., Zhang, Y., The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 2005, 6, 838-849.
149. Le Romancer, M., Treilleux, I., Leconte, N., Robin-Lespinasse, Y. et al., Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Molec. Cell 2008, 31, 212-221.
150. Wagner, S., Weber, S., Kleinschmidt, M. A., Nagata, K. et al., SET-mediated promoter hypoacetylation is a pre-requisite for coactivation of the estrogen-responsive pS2 gene by PRMT1. J. Biol. Chem. 2006, 281, 27242-27250.
151. Nilson, T. W., Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet. 2007, 23, 243-249.
152. Zhao, S., Liu, M. F., Mechanisms of microRNA mediated gene regulation. Sci. China C. Life Sci. 2009, 52, 1111-1116.
153. Parker, L. P., Taylor, D. D., Kesterson, J., Metzinger, D. S. et al., Modulation of microRNA associated with ovarian cancer cells by genistein. Eur. J. Gynaecol. Oncol. 2009, 30, 616-621.
154. Li, Y., Vandenboom, T. G., Kong, D., Wang, Z. et al., Upregulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69, 6704-6712.
155. Li, Y., Vandenboom, T. G., Wang, Z., Kong, D. et al., MiR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010, 70, 1486-1495.
156. Sun, Q., Cong, R., Yan, H., Gu, H. et al., Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol. Rep. 2009, 22, 563-567.
157. Zhang, Q.-X., Hilsenbeck, S. G., Fuqua, S. A. W., Borg, Å., Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J. Steroid Biochem. Mol. Biol. 1996, 59, 251-260.
158. Lu, B., Leygue, E., Dotzlaw, H., Murphy, L. J. et al., Estrogen receptor-β mRNA variants in human and murine tissues. Mol. Cell. Endocrinol. 1998, 138, 199-203.
159. Davies, M. P. A., O'Neill, P. A., Innes, H., Sibson, D. R. et al., Correlation of mRNA for oestrogen receptor beta splice variants ERβ1, ERβ2/ERβcx and ERβ5 with outcome in endocrine-treated breast cancer. J. Mol. Endocrinol. 2004, 33, 773-782.
160. Auboeuf, D., Batsche, E., Dutertre, M., Muchardt, C. et al., Coregulators: transducing signal from transcription to alternative splicing. Trends Endocrinol. Metab. 2007, 18, 122-129.
161. Sotoca, A. M., Vervoort, J., Rietjens, I. M. C. M., Gustafsson, J-Å., Human ERα and ERβ splice variants: understanding their domain structure in relation to their biological roles in breast cancer cell proliferation. Biochemistry, 2012, Chapter 5, pp 141-160.